Treatment of malignant gliomas: radiotherapy, chemotherapy and integration of new targeted agents

References

• Thiessen B, Maguire JA, McNeil K et al. Loss of heterozygosity for loci on chromosome arms lp and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. j Neuro-oncol 64,271–278 (2003).
   PubMedGoogle Scholar
• Hashimoto N, Murakami M, Takahashi Y et al Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm lp. Cancer 97,2254–2261 (2003).
   PubMedGoogle Scholar
• Laws ER, Pamey IF, Huang W et al Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. I Neurosurg. 99,467–473 (2003).
   PubMed Web of Science ®Google Scholar
• Curran WJ, Scott CB, Horton J et al Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. .1. Natl Cancer Inst. 85, 704–710 (1993).
   Google Scholar
• Guderson S, Lote K, Hannisdal E. Prognostic factors for glioblastoma multiforme. Acta Oncol 35,123–127 (1996).
   Google Scholar
• MRC Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. Neuro-oncol 9,47–55 (1990).
   Google Scholar
• Simpson JR, Horton J, Scott CB et al Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive RTOG clinical trials. Intl. Radiat. Oncol Biol. 26, 239–244 (1993).
   PubMed Web of Science ®Google Scholar
• Stemmer-Rachamimov AO, Louis DN. Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr. Opin. Oncol 9,230–234 (1997).
   Google Scholar
• Nieder C, Petersen S, Petersen C et al The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 26,67–73 (2000).
   PubMed Web of Science ®Google Scholar
• Smith JS, Tachibana I, Passe SM et al PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Natl Cancer Inst. 93,1246–1256 (2001).
   Google Scholar
• Seiferheld W Chakravarti A, Ang KK et al. Overexpression of the epidermal growth factor receptor (EGFR), as determined by EGFR immunostaining on tissue microarrays, fails to demonstrate independent prognostic value for patients with glioblastoma multiforme: a report from RTOG 7401, 7918, 8302, 8409, 9006, 9305, 9602 and 9806 (abstract 161). Int. J Radiat. Oncol Biol. Phys. 54, 96 (2002).
   Google Scholar
• Simmons ML, Lamborn KR, Takahashi M et al Analysis of complex relationships between age, p53, epidermal growth factor receptor and survival in glioblastoma patients. Cancer Res. 61, 1122–1128 (2001).
   PubMed Web of Science ®Google Scholar
• •Thoughtful analysis of emerging prognostic factors.
   Google Scholar
• Schmidt MC, Antweiler S, Urban N et al. Impact of genotype and morphology on the prognosis of glioblastoma. I Neuropathol Exp. Neural 61, 321–328 (2002).
   PubMed Web of Science ®Google Scholar
• Brat DJ, Seiferheld W Perry A et al FISH analysis of genetic markers of prognosis for high grade astrocyotmas using tissue microarrays from RTOG clinical trials. Radiation Therapy Oncology Group Translational Research Program. Int.j Radiat. Oncol Biol. fiys. 57(Suppl), S135 (2003).
   Google Scholar
• Nutt CL, Mani DR, Betensky RA et al Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602–1607 (2003).
   PubMed Web of Science ®Google Scholar
• ••Valuable introduction to the field ofmodern classification methods.
   Google Scholar
• Shai R, Shi T, Kremen TJ et a/. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22, 4918–4923 (2003).
   Google Scholar
• Mischel PS, Shai R, Shi T et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 22, 2361–2373 (2003).
   PubMed Web of Science ®Google Scholar
• Kuznetsov YE, Caramanos Z, Antel SB et al Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery53, 565–574 (2003).
   PubMed Web of Science ®Google Scholar
• Zhu A, Shaeffer J, Leslie S et al Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. int. j Radiat. Oncol Biol. Phys. 34, 809–815 (1996).
   PubMed Web of Science ®Google Scholar
• Silber JR, Blank A, Bobola MS et al 0- methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res. 5, 807–814 (1999).
   Google Scholar
• Friedman HS, McLendon RE, Kerby T et al DNA mismatch repair and 06-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. j Clin. Oncol 16, 3851–3857 (1998).
   Google Scholar
• Schiff D, Shaffrey ME. Role of resection for newly diagnosed malignant gliomas. Expert Rev AntiCancer Ther. 3, 621–30 (2003).
   PubMedGoogle Scholar
• Nieder C, Andratschke N, Wiedenmann N et al Radiotherapy for high-grade gliomas: does altered fractionation improve the outcome? Strahlenther. °filo'. 180, (2004) (In Press).
   Google Scholar
• •Summary of currently achievable results with standard treatments.
   Google Scholar
• Fitzek MM, Thornton AF, Rabinov JD et al Accelerated fractionated proton/ photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a Phase II prospective trial. 1 Neurosurg. 91, 251–260 (1999).
   Google Scholar
• Chan JL, Lee SW, Fraass BA et al Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin. Oncol 20, 1635–1642 (2002).
   PubMed Web of Science ®Google Scholar
• Laperriere NJ, Leung PM, McKenzie S et al Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. int. j Radiat. Oncol Biol. Phys. 41, 1005–1011 (1998).
   PubMed Web of Science ®Google Scholar
• Selker RG, Shapiro WR, Burger P et al The Brain Tumor Co-operative Group NIH Trial 87-01: a randomised comparison of surgery, external radiotherapy and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy and carmustine. Neurosurgery51, 343–355 (2002).
   PubMed Web of Science ®Google Scholar
• McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin. Surg. Oncol 14, 79–87 (1998).
   Google Scholar
• Sneed PK, Stauffer PR, McDermott MW et al Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. int. j Radiat. Oncol Biol. Phys. 40, 287–295 (1998).
   PubMed Web of Science ®Google Scholar
• Prados MD, Wara WM, Sneed PK et a/. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int. J Radiat. Oncol Biol. Phys. 49, 71–77 (2001).
   Google Scholar
• Shafman TD, Loeffler JS. Novel radiation technologies for malignant gliomas. CUI7: Opin. Oncol 11, 147–151 (1999).
   Google Scholar
• Kleinberg L, Grossman SA, Carson K et al. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a Phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. Clin. Oncol 20, 3149–3155 (2002).
   Google Scholar
• Williams JA, Williams JR, Yuan X et al Protracted exposure radiosensitization of experimental human malignant glioma. Radiat. Oncol Invest. 6, 255–263 (1998).
   PubMedGoogle Scholar
• Fine HA, Dear KB, Loeffler JS et al Meta- analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high- grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011–1018 (2002). Most recent meta-analysis of chemotherapy in malignant gliomas.
   Google Scholar
• Buckner JC, Schomberg PJ, McGinnis WL et al A Phase III study of radiation therapy plus carmustine with or without recombinant interferon-CL in the treatment of patients with newly diagnosed high-grade glioma. Cancer92, 420–433 (2001).
   PubMed Web of Science ®Google Scholar
• Shapiro WR, Green SB, Burger PC et al Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Co-operative Group Trial 8001.1 Neurosurg. 71, 1–9 (1989).
   Google Scholar
• Grossman SA, O'Neill A, Grunnet M et al Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Co-operative Oncology Group Trial 2394.1 Clin. Oncol 21, 1485–1491 (2003).
   Google Scholar
• Gilbert M, O'Neill A, Grossman S et al A Phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme: an Eastern Co-operative Oncology Group study (E2393). I Neuro-oncol 47, 145–152 (2000).
   PubMed Web of Science ®Google Scholar
• Levin VA, Yung WK, Bruner J et al Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int. J. Radiat. Oncol Biol. Phys. 53, 58–66 (2002).
   PubMedGoogle Scholar
• Jeremic B, Shibamoto Y, Grujicic D et al Concurrent accelerated hyperfractionated radiation therapy and carboplatin/ etoposide in patients with malignant glioma: long-term results of a Phase II study. Neuro-oncol 51,133–141 (2001).
   Google Scholar
• Brandes AA, Rigon A, Zampieri P et al Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a Phase II study. Cancer 82,355–361 (1998).
   PubMed Web of Science ®Google Scholar
• Levin VA, Silver P, Hannigan J et al Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. .1. Radiat. Oncol Biol. Phyc. 18, 321–324 (1990).
   Google Scholar
• Levin VA, Hess KR, Choucair A et al Phase III randomised study of postradiotherapy chemotherapy with combination a-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Gun. Cancer Res. 9, 981–990 (2003).
   Google Scholar
• Weller M, Muller B, Koch R et al. Neuro- Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. j Clin. Oncol 21,3276–3284 (2003).
   Google Scholar
• Durando X, Lemaire JJ, Tortochaux J et al High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 31, 559–564 (2003).
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E et al A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. I Neuro-oncol 5,79–88 (2003).
   PubMed Web of Science ®Google Scholar
• Degen RV, Walbridge S, Vortmeyer AO et al Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. Neurosurg. 99,893–898 (2003).
   Web of Science ®Google Scholar
• Debinski W Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest. 20,801–809 (2002).
   Google Scholar
• Kunwar S. Convection enhanced delivery of 1L13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase 1 studies. Acta Neurochir. Suppl 88,105–111 (2003).
   Google Scholar
• Weber FVV, Floeth F, Asher A et al Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. 88(Suppl.), 93–103 (2003).
   Google Scholar
• Langer CJ, Ruffer J, Rhodes H et al Phase II Radiation Therapy Oncology Group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int. Radiat. OncoiBioiPhys.51, 113–119 (2001).
   Google Scholar
• Fisher B, Won M, Macdonald D et al Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int. Radiat. Oncol Phys. 53,980-986 (2002).
   Google Scholar
• Raymond E, Fabbro M, Boige V et al Multicentre Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol 14,603–614 (2003).
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann Kraljevic S et al Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. j Clin. Oncol 20, 1375–1382 (2002).
   PubMed Web of Science ®Google Scholar
• Von Bossanyi P, Diete S, Dietzmann K et al Immunohistochemical expression of P-glycoprotein and glutathione 5-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol 94,605–611 (1997).
   PubMed Web of Science ®Google Scholar
• Tuvesson H, Gunnarsson PO, Seidegard J. Measurement and characterization of the denitrosation of tauromustine and related nitrosoureas by glutathione transferases in liver cytosol from various species. Carcinogenesis 14,1143–1147 (1993).
   Google Scholar
• Wolff J, Denecke J, Jurgens H et al Dexamethasone induces partial resistance to cisplatinum in C6 glioma cells. Anticancer Res. 16,805–810 (1996).
   PubMed Web of Science ®Google Scholar
• Naumann U, Durka S, Weller M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation. Oncogene 17,1567–1575 (1998).
   Google Scholar
• Belanich M, Pastor M, Randall T et al Retrospective study of the correlation between DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 56,783–788 (1996).
   PubMed Web of Science ®Google Scholar
• Ruan S, Okcu MF, Pong RC et al. Attenuation of WAF1/Cipl expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis (2 -chloroethyl) - 1-nitrosourea and cisplatin. Clin. Cancer Res 5,197–202 (1999).
   Google Scholar
• Chce G, Horvath S, Cloughesy TF et al Analysis of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63,2742–2746 (2003).
   PubMedGoogle Scholar
• Eshleman JS, Carlson BL, Mladek AC et al Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res. 62,7291–7297 (2002).
   PubMed Web of Science ®Google Scholar
• Nakatani K, Yoshimi N, Mori H et al The significance of the expression of tumor suppressor gene DCC in human gliomas. Neum-oncol 40,237–242 (1998).
   PubMedGoogle Scholar
• Mitzumatsu S, Tamiya T, Ono Y et al Expression of cell cycle regulator p27K11)1 is correlated with survival of patients with astrocytoma. Clin. Cancer Res. 5,551-557 (1999).
   Google Scholar
• Nieder C, Schlegel J, Andratschke N et al The role of growth factors in central nervous system tumours. Anti Cancer Res. 23,1681–1686 (2003).
   PubMed Web of Science ®Google Scholar
• Barker FG II, Simmons ML, Chang SM et al EGFR overexpression and radiation response in glioblastoma multiforme. Int. J. Radiat. arca Biol. Phys. 51,410–418 (2001).
   PubMedGoogle Scholar
• Chakravarti A, Delaney MA, Noll E et al Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin. Cancer Res. 7, 2387–2395 (2001).
   PubMedGoogle Scholar
• Muracciole X, Romain S, Dufour H et al PM-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. int. j Radiat. Oncol Biol. Phys. 52,592-598 (2002).
   Google Scholar
• Lammering G, Valerie K, Lin PS et al Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin. Cancer Res. 7, 682–690 (2001).
   PubMed Web of Science ®Google Scholar
• Lammering G, Hewit TH, Valerie K et al AntierbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int. .1. Radiat. Biol. 79, 561–568 (2003).
   Google Scholar
• •Valuable overview of antiepiderrnal growth factor (EGFR) strategies in conjunction with radiotherapy.
   Google Scholar
• Li B, Chang CM, Yuan M et al Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. 63,7443–7450 (2003).
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositol 3-kinase signaling. Cancer Res. 62,200-207 (2002).
   Google Scholar
• Johns TG, Luwor RB, Murone C et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc. Natl. Acad. Sc]. USA (2003).
   Google Scholar
• •Intriguing data on combined antiEGFR strategies.
   Google Scholar
• Chakravarti A, Chaldadar A, Delaney MA, Latham DE, Loeffler JS. The epidermal receptor growth factor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 62, 4307–4315 (2002).
   Google Scholar
• Rich JN, Reardon DA, Peery T et al Phase II trial of gefitinib in recurrent glioblastoma. I Clin. Oncol 22,133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Jennings MT, Pietenpol JA. The role of transforming growth factor 3 in glioma progression. I Neuro-oncol 36,123–140 (1998).
   PubMed Web of Science ®Google Scholar
• Wick W Platten M, Weller M. Glioma cell invasion: regulation of metalloproteinase activity by TGF-0. I Neuro-oncol 53, 177–185 (2001).
   PubMedGoogle Scholar
• Fakhrai H, Dorigo 0, Shawler DL et al Eradication of established intracranial rat gliomas by transforming growth factor antisense gene therapy. Proc. Natl Acad. Sc]. USA 93,2909–2914 (1996).
   Google Scholar
• Trojan J, Johnson TR, Rudin SD et al Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor-1 RNA. Science 259,94–97 (1993).
   PubMedGoogle Scholar
• Andrews DW, Resnicoff M, Flanders AE et al Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor Type I receptor in malignant astrocytomas. I Clin. Oncol 19, 2189–2200 (2001).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Hess K et al Phase I study of 5TI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99–08, Abstract 288). Pmc. Am. Soc. Clin. Oncol 21,73 (2002).
   Google Scholar
• Schueneman AJ, Himmelfarb E, Geng L et al SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63,4009–4016 (2003).
   PubMed Web of Science ®Google Scholar
• •Good example of antiangiogenic receptor tyrosine kinases approaches.
   Google Scholar
• Fukumura D, Xu L, Chen Y et al Hypoxia and acidosis independently upregulate vascular endothelial growth factor transcription in brain tumours in vivo. Cancer Res. 61,6020–6024 (2001).
   PubMed Web of Science ®Google Scholar
• Geng L, Donnelly E, McMahon G et al Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61,2413–2419 (2001).
   PubMed Web of Science ®Google Scholar
• Yung WA, Friedman H, Jackson E et al A Phase I trial of PTK787/ZK 222584 (PTK/ ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma (Abstract 315). Proc. Am. Soc. Clin. Oncol 21,79 (2002).
   Google Scholar
• Auguste P, Gursel DB, Lemiere S et al Inhibition of fibroblast growth factor/ fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res. 61,1717–1726 (2001).
   PubMed Web of Science ®Google Scholar
• Fine HA, Wen PY, Maher EA et al Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. I Clin. awl 21,2299–2304 (2003).
   Google Scholar
• Seiferheld W Mehta MP, Delrowe J et al 5 years of glioblastoma multiforme (GBM) Phase II trials at the Radiation Therapy Oncology Group (RTOG) (Abstract 281). Proc. Am Soc. Clin. Oncol 21,71 (2002).
   Google Scholar
• Kim JH, Kolozsvary A, Rogulski K et al Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene. Cancer 1 Su. Am. 4,364-369 (1998).
   Google Scholar
• Fulda S, Wick W Weller M, Debatin KM. Smac agonists sensitize for Apo2UTRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nature Merl 8,808–815 (2002).
   PubMed Web of Science ®Google Scholar
• Emrich JG, Brady LW, Quang TS et al Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am. I Clin. Oncol 25, 541–546 (2002).
   Google Scholar
• •Largest series of antibody-treated patients.
   Google Scholar
• Reardon DA, Akabani G, Coleman RE et al Phase II trial of murine (131)1-labeled antitenascin monoclonal antibody 8106 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. j Clin. Oncol 20,1389–1397 (2002).
   Google Scholar
• Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer 1 9,157–166 (2003).
   Google Scholar
• Yamanaka R, Abe T, Yajima N et al Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. BE I Cancer 89, 1172–1179 (2003).
   Google Scholar
• Price A, Shi Q, Morris D et al Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5,845-854 (1999).
   Google Scholar
• Delmas C, End D, Rochaix P et al The famesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin. Cancer Res. 9, 6062–6068 (2003).
   Google Scholar
• Komata T, Kanzawa T, Kondo Y et al Telomerase as a therapeutic target for malignant gliomas. Oncogene 21,656–663 (2002).
   PubMed Web of Science ®Google Scholar